RDACCQV: Quality of Life Comparison in Patients With Different Types of Alopecia

Sponsor
Centre Hospitalier Universitaire, Amiens (Other)
Overall Status
Completed
CT.gov ID
NCT04246957
Collaborator
(none)
100
1
20.5
4.9

Study Details

Study Description

Brief Summary

Hair loss is a frequent cause of patient consultation in dermatology. It is known to have a strong impact on patients' quality of life for many reasons; such as esthetic aspect, financial implications, social consequences. Numerous studies have assessed the impact of some types of alopecia on patients' quality of life. One study compared the quality of life in patients with scarring alopecia with patients of non-scarring alopecia. No studies have compared quality of life between the different types of scarring alopecia nor different types of non-scarring alopecia. However, none have assessed the impact on the patient partner quality of life. In addition, few treatments for alopecia are covered by national health insurance in France. The main objective is to compare the impact on the quality of life in different types of alopecia. By using the average scores of the questionnaire Dermatology Life Quality Index (DLQI) for each type of alopecia.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: general quality of life questionary
  • Behavioral: specific quality of life questionary

Study Design

Study Type:
Observational
Actual Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Quality of Life Comparison in Patients With Different Types of Alopecia
Actual Study Start Date :
Mar 4, 2019
Actual Primary Completion Date :
Nov 16, 2020
Actual Study Completion Date :
Nov 16, 2020

Outcome Measures

Primary Outcome Measures

  1. Variation of score of questionnaire Dermatology Life Quality Index (DLQI) according alopecia type in patient life [at day 0]

    The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. It is designed for people aged 16 years and above. There are 10 questions, covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, treatment. Each question refers to the impact of the skin disease on the patient's life over the previous week. Each question is scored from 0 to 3, giving a possible score range form 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

Secondary Outcome Measures

  1. Variation of score of questionnaire Dermatology Life Quality Index (DLQI) according alopecia type in spouse life [at day 0]

    The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. It is designed for people aged 16 years and above. There are 10 questions, covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, treatment. Each question refers to the impact of the skin disease on the patient's life over the previous week. Each question is scored from 0 to 3, giving a possible score range form 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients affiliated to social security

  • patients able to understand and fill out a questionnaire

  • patients over 18 years old

  • patient consulting in the dermatology department of Amiens University Hospital for a primary alopecia

Exclusion Criteria:
  • minors

  • patients under guardianship, deprived of liberty

  • scalp affections other than alopecia

  • secondary alopecia

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Amiens Amiens France 80480

Sponsors and Collaborators

  • Centre Hospitalier Universitaire, Amiens

Investigators

  • Principal Investigator: Catherine LOK, Pr, CHU Amiens
  • Principal Investigator: Thomas Baltazard, MD, CHU Amiens
  • Principal Investigator: Nesrine Zitouni, MD, CHU Amiens
  • Principal Investigator: Fanny Dessirier, MD, CHU Amiens

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier:
NCT04246957
Other Study ID Numbers:
  • PI2019_843_0001
First Posted:
Jan 29, 2020
Last Update Posted:
Dec 2, 2020
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire, Amiens
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 2, 2020